SMS Pharmaceuticals Limited manufactures Active Pharma Ingredients (APIs) and intermediates, with multiple FDA-compliant facilities in Hyderabad and Andhra Pradesh. The company is a leader in the production of APIs and leverages its extensive R&D capabilities to maintain its market position.

The company reported an 80% year-on-year increase in profit after tax for Q2 FY26, driven by a strategic focus on backward integration and volume growth across key APIs.

A major ₹280 crore capital expenditure program is underway, aimed at expanding production capacities and enhancing the company's market footprint by November 2026.

SMS Pharmaceuticals maintains a diversified product portfolio across over 55 APIs in 14 therapeutic segments, mitigating market risks and enhancing revenue stability.

Strategic partnerships, such as the joint venture with Chemo, have significantly bolstered the company's position in the regulated markets, leading to first-to-market advantage in the anti-diabetic segment.